Orciprenaline (Metaproterenol)

Subscribe to Selected New Research on Orciprenaline

284 relevant articles (28 outcomes, 28 trials/studies) found for this Drug

Description: A beta-adrenergic agonist used in the treatment of asthma and bronchospasms.

Also Known As:

Metaproterenol; Alupent; Alotec; Astmopent; Metaprel; Metaproterenol Polistirex; Metaproterenol Sulfate; Polistirex, Metaproterenol; 1,3-Benzenediol, 5-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-

Relationship Network

Drug Context: Research Results

Experts

1.	Grimm, David: 1 article (01/2004)
2.	Lesser, Marvin: 1 article (01/2004)
3.	Spungen, Ann M: 1 article (01/2004)
4.	Schilero, Gregory J: 1 article (01/2004)
5.	Lenner, Roberta: 1 article (01/2004)
6.	Barnewolt, B A: 1 article (06/2001)
7.	Walter, F G: 1 article (06/2001)
8.	Bey, T A: 1 article (06/2001)

Related Diseases

1.	Asthma (Bronchial Asthma) 07/01/1986 - "In conclusion, aerosolized metaproterenol was well tolerated in acute childhood asthma in repeated doses, and it appeared to be associated with prolonged bronchodilation and improved outcome." 03/01/1986 - "OTC metaproterenol will aid improvement in asthma care." 08/01/1999 - "A double blind, randomized trial of two regimens of nebulized metaproterenol was conducted in patients presenting to an Emergency Department with an acute asthma exacerbation. " 06/01/1990 - "The dose-response relationship of single doses of nebulized metaproterenol sulfate 5% inhalant solution was evaluated by placebo-controlled, parallel-group study of 30 children, aged 3 to 6 years old, with stable asthma. " 02/01/1987 - "Double-blind, dose-response study of metaproterenol inhalant solution in children with acute asthma." Order ALL the reference details at left...
2.	Bronchial Spasm 07/01/1995 - "One patient's pulse rate increased to more than 200 beats/min. Although effective in reversing bronchospasm, the side effects of metaproterenol when used in rapid sequence are of major concern." 10/01/1996 - "Comparison of inhaled metaproterenol via metered-dose and hand-held nebulization in prehospital treatment of bronchospasm." 09/01/1987 - "The dose-related effects of inhaled 5% metaproterenol solution in asthmatic children between the ages of six and 12 years with acute bronchospasm were evaluated. " 01/01/1988 - "In conclusion, metaproterenol is superior to cromolyn in protecting against cold-air-induced bronchospasm." 01/01/1988 - "Inhaled metaproterenol is superior to inhaled cromolyn in protecting against cold-air-induced bronchospasm." Order ALL the reference details at left...
3.	Chronic Obstructive Pulmonary Disease (COPD) 01/29/1996 - "These results suggest that the combination of iprathropium bromide and metaproterenol inhalation solutions offers a potential therapeutic advantage to patients with symptomatic COPD over nebulized metaproterenol alone without the risk of increased side effects." 01/01/1994 - "To investigate the relationship between the emphysematous changes and bronchodilator responses in patients with chronic airflow obstruction (CAO), we studied the correlation between bronchodilator response to 10 mg inhaled metaproterenol and the extent of emphysema, using selective alveolobronchogram (SAB). " 02/01/1986 - "To evaluate comparative bronchodilator efficacy with chronic airflow obstruction (CAO), we randomly administered to ten patients week-long treatments consisting of: inhaled metaproterenol from a metered dose canister (1.30 mg six times a day) and doses of a sustained-release theophylline formulation sufficient to achieve plasma levels of 10-15 micrograms/ml; metaproterenol-placebo; theophylline-placebo; or placebo-placebo. " 04/01/1984 - "In our experience, oxygen and inhaled metaproterenol are effective treatment for exacerbations of COPD." 04/01/1991 - "Thus, ipratropium and metaproterenol similarly improved pulmonary function in COPD patients when stable and during acute exacerbations." Order ALL the reference details at left...
4.	Heart Failure 04/01/1979 - "In acute myocardial failure during anaesthesia or in "low cardiac ouptut" following open heart surgery no improvement in myocardial contractility is obtained by i.v.-application of potassium-canrenoate; at the present there seems no alternative to other positive inotropic agents such as calcium, glucagon, dopamine, orciprenaline and epinephrine." 04/01/1992 - "Premodulation of acute heart failure with membrane protective agents (unithiol, alpha-tocopherol, hydrocortisone), pharmacological antagonists (novodrin, alupent, isoprenaline), and the cardiotonic agent dobutamine enabled acute heart failure to be effectively treated, hemosorption to be made in early periods and cardiac events to be abolished in 80% of the patients, SCA mortality rates decreased from 11.7 to 3.2%." Order ALL the reference details at left...
5.	Lung Diseases (Lung Disease) 01/01/1987 - "Effects of metaproterenol on pulmonary mechanics, oxygenation, and ventilation in infants with chronic lung disease." 12/15/1965 - "[On the effects of Alotec on chronic obliterative lung diseases with reference to respiratory function tests]" 01/01/1987 - "These data show that bronchospasm contributes significantly to the high pulmonary resistance in preterm infants with chronic lung disease and that metaproterenol is beneficial in the therapy of infants with chronic lung disease requiring mechanical ventilation." 01/01/1987 - "Changes in pulmonary resistance, dynamic compliance, tidal volume, and transcutaneous PO2 and PCO2 after nebulized administration of metaproterenol were evaluated in eight newborn infants (birth weight 650 to 1060 g, gestational age 25 to 28 weeks) with chronic lung disease receiving mechanical ventilation. " 01/01/2002 - "The database search used the following terms: Wheeze or asthma and Infant or Child and Short acting beta-agonist or Salbutamol (variants), Albuterol, Terbutaline (variants), Orciprenaline, Fenoterol SELECTION CRITERIA: Randomised controlled trials comparing the effect of b2-agonist against placebo in children under 2 years of age who had had two or more previous episodes of wheeze, not related to another form of chronic lung disease. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Orciprenaline (Metaproterenol)
2.	Epinephrine (Adrenaline)
3.	Theophylline (Theon)
4.	Ipratropium (Ipratropium Bromide)
5.	Adrenergic beta-Agonists (beta-Adrenergic Agonists)
6.	Cromolyn Sodium (Cromoglicic Acid)
7.	Aminophylline (Carine)
8.	Glycopyrrolate (Glycopyrronium Bromide)
9.	Albuterol (Salbutamol)
10.	Terbutaline (Brethaire)

Related Therapies and Procedures

1.	Metered Dose Inhalers (Metered Dose Inhaler)
2.	Nebulizers and Vaporizers (Inhaler)
3.	Artificial Respiration (Mechanical Ventilation)
4.	Intravenous Infusions
5.	Resuscitation

Best Treatments:
Research Summary Report
on Asthma

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2978 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>